Eli Lilly Partners with Profluent on $2.25B AI-Designed DNA-Editing Drug Deal
Gate News message, April 29 — US pharmaceutical company Eli Lilly announced on April 28 it signed a deal worth up to $2.25 billion with AI biotech startup Profluent to develop DNA-editing medicines. Lilly will receive exclusive rights to any medicines resulting from the partnership.
The companies d
GateNews·04-29 01:51
